L'intérêt à découvert pour Global X Blockchain & Bitcoin Strategy ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Global X Blockchain & Bitcoin Strategy ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Global X Blockchain & Bitcoin Strategy ETF (NASDAQ:BITS), Rapport sur les intérêts à découvert

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing directly or indirectly in equity securities of U.S. and non-U.S. Blockchain Companies, as defined below, and in long positions in U.S. listed bitcoin futures (Bitcoin Futures) contracts. As of the date of this Prospectus, the Fund intends to gain exposure to Blockchain Companies by investing indirectly in underlying ETFs holding Blockchain Companies, including the passively-managed affiliated Global X Blockchain ETF. Such investment in underlying ETFs holding Blockchain Companies may be used to provide most, or even all, of the Funds exposure to Blockchain Companies, and it is possible that the Fund may or may not invest directly in any Blockchain Companies. Such Bitcoin Futures contracts will be standardized, cash-settled bitcoin futures contracts traded on commodity exchanges registered with the Commodity Futures Trading Commission (CFTC). Currently, the only such contracts are traded on, or subject to the rules of, the Chicago Mercantile Exchange (CME). Under normal circumstances, the Fund will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in Blockchain Companies and in long positions on U.S. listed Bitcoin Futures contracts. Under normal circumstances, the Fund will invest at least 25% of its assets in Blockchain Companies and will have notional exposure to Bitcoin Futures equal to at least 20% of the total assets of the Fund. The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed.

Global X Blockchain ETF

Global X 1-3 Month T-Bill Mutual Fund

Global X Blockchain & Bitcoin Strategy ETF

BitShares

Bitspawn

WIIM

Genius Group shares are trading higher after the company announced a share buyback approval for up to one million shares.

Goldman Sachs analyst James Schneider initiates coverage on NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy rating and announces Price Target of $185.

News

Price Target

Initiation

Analyst Ratings

NVDA

Goldman Sachs Initiates Coverage On NVIDIA with Buy Rating, Announces Price Target of $185

Keybanc analyst Jason Celino maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Overweight and raises the price target from $340 to $358.

CDNS

Keybanc Maintains Overweight on Cadence Design Systems, Raises Price Target to $358

BLNK

Blink Charging And Axxeltrova Capital To Pursue £100M Special Purpose Vehicle

ZENA

ZenaTech Creates First Quantum Computing Prototype For AI Drone Solutions

Wells Fargo analyst Tiago Fauth downgrades Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) from Overweight to Equal-Weight and lowers the price target from $138 to $107.

Downgrades

VRNA

Wells Fargo Downgrades Verona Pharma to Equal-Weight, Lowers Price Target to $107

Goldman Sachs analyst James Schneider initiates coverage on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy rating and announces Price Target of $225.

AMAT

Goldman Sachs Initiates Coverage On Applied Mat with Buy Rating, Announces Price Target of $225

<a href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" title="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx">https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx</a>

MRNA

Moderna Receives Full FDA Approval for COVID-19 Vaccine, Spikevax, In Children Aged 6 Months Through 11 Years At Increased Risk For COVID-19 Disease

Macro Economic Events

Econ #s

Economics

USA Continuing Jobless Claims 1,965K Vs 1,980K Est.

Goldman Sachs analyst James Schneider initiates coverage on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Neutral rating and announces Price Target of $20.

AMKR

Goldman Sachs Initiates Coverage On Amkor Tech with Neutral Rating, Announces Price Target of $20

US Initial Jobless Claims 227K vs 236K Est.

Goldman Sachs analyst James Sheehan initiates coverage on GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral rating and announces Price Target of $40.

Goldman Sachs Initiates Coverage On GLOBALFOUNDRIES with Neutral Rating, Announces Price Target of $40

HTOO

Fusion Fuel Green shares are trading lower after the company announced a 1-for-35 reverse stock split to regain Nasdaq minimum bid price rule compliance.

Goldman Sachs analyst James Sheehan initiates coverage on Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Western Digital with Neutral Rating, Announces Price Target of $130

D. Boral Capital analyst Jesse Sobelson maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $15 price target.

EVTL

D. Boral Capital Maintains Buy on Vertical Aerospace, Maintains $15 Price Target

PASG

Passage Bio shares are trading lower after the company announced a 1-for-20 reverse stock split.

Goldman Sachs analyst James Sheehan initiates coverage on Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Micron Technology with Neutral Rating, Announces Price Target of $130

KLTO

Klotho Neurosciences shares are trading higher after the company announced the FDA has awarded orphan drug status for KLTO-202 for novel gene therapy in amyotrophic lateral sclerosis patients.

Goldman Sachs analyst James Schneider initiates coverage on Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral rating and announces Price Target of $85.

ENTG

Goldman Sachs Initiates Coverage On Entegris with Neutral Rating, Announces Price Target of $85

As JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) prepares to unveil its second-quarter earnings on July 15, the financial world is bracing for a significant shift that reflects broader economic trends. Over the past year, rising interest rates and inflationary pressures have squeezed borrowers and heightened market volatility, factors that are expected to dampen <a href="https://www.benzinga.com/quote/JPM/earnings">the bank&#8217;s profits.</a>
Analysts expect the company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Wednesday, Truist Securities analyst John McDonald maintained a Hold rating on JPMorgan and raised the price target from $280 to $290.
With the recent buzz around JPMorgan, some investors may be eyeing potential gains from the company's dividends. As of now, JPMorgan offers an annual dividend yield of 1.98%, which is a quarterly dividend amount of $1.40 per share ($5.60 a year).
To figure out how to earn $500 monthly from JPMorgan, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by JPMorgan's $5.60 dividend: $6,000 / $5.60 = 1,071 shares.
So, an investor would need to own approximately $303,264 worth of JPMorgan, or 1,071 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $5.60 = 214 shares, or $60,596 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
JPM Price Action: Shares of JPMorgan gained by 0.1% to close at $283.16 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo: Rokas Tenys/Shutterstock

Comments

Global X Blockchain & Bitcoin Strategy ETF

Intérêt court

Global X Blockchain & Bitcoin Strategy ETF (NASDAQ:BITS), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL